To investigate the effect of three anticancer drugs (mitomycin c (MMC), doxorubicin or gemcitabine) on bladder wall morphology and the uptake of paclitaxel or docetaxel following coadministration. The primary objective of this study was to measure the uptake of MMC, doxorubicin or gemcitabine with or without exposure of the tissue to amine terminated cationic nanoparticles (CNPs) and to investigate any possible exfoliation effects of the three drugs on intact bladder tissue. The secondary objective was to investigate the uptake of taxane drugs (docetaxel, DTX) and paclitaxel, (PTX) from surfactant micelle formulations in the presence of MMC, doxorubicin or gemcitabine.
Objective
To investigate the effect of three anticancer drugs (mitomycin c (MMC), doxorubicin or gemcitabine) on bladder wall morphology and the uptake of paclitaxel or docetaxel following coadministration. The primary objective of this study was to measure the uptake of MMC, doxorubicin or gemcitabine with or without exposure of the tissue to amine terminated cationic nanoparticles (CNPs) and to investigate any possible exfoliation effects of the three drugs on intact bladder tissue. The secondary objective was to investigate the uptake of taxane drugs (docetaxel, DTX) and paclitaxel, (PTX) from surfactant micelle formulations in the presence of MMC, doxorubicin or gemcitabine.
Materials and Methods
Sections of fresh pig bladder tissue were incubated in Franz diffusion cells with the urothelial side exposed to solutions of doxorubicin, MMC and gemcitabine containing radioactive drug for 90 min. Some tissue samples were simultaneously exposed to each of the three drugs in combination with the surfactant micelle formulations of PTX (Taxol) or DTX (Taxotere). Tissue sections were then cryostat sectioned for drug quantitation by liquid scintillation counting or fixed for scanning electron microscopy and haematoxylin and eosin staining.
Results
All three drugs caused exfoliation of the urothelial layer of bladder tissues. Drug uptake studies showed that all three drugs effectively penetrated the lamina propria through to the muscular layer over a 2-h incubation and these levels were unaffected by pre-treatment with CNPs. The uptake levels of the taxane drugs PTX and DTX were significantly enhanced following simultaneous treatment of bladders with MMC, doxorubicin or gemcitabine.
Conclusion
The exfoliation effects of MMC, doxorubicin and gemcitabine allow for good tissue penetration of these drugs with no additional effect from CNP treatment of bladders. The observed exfoliation effect of these amine-containing drugs probably arises from a cationic interaction with the mucus and urothelium cell layer in a manner similar to that previously reported for CNPs. These studies suggest that the lack of long-term clinical efficacy of these drugs may not arise from poor intravesical drug penetration but may result from a rapid diffusion of the drugs into the deeper vascularised muscular region with rapid drug clearance. The enhanced uptake of PTX or DTX following co-administration with MMC, doxorubicin or gemcitabine probably arises from
Introduction
In the USA in 2017, there were an estimated 79 000 newly diagnosed cases of bladder cancer, with an estimated prevalence of 696 440 people living with bladder cancer and >16 000 deaths from bladder cancer [1] . In all, 75-80% of bladder tumours present as non-muscleinvasive bladder cancer (NMIBC) and the remainder as muscle-invasive bladder cancer (MIBC) [2] . NMIBC is categorised both in terms of stage (Ta, T1 and carcinoma in situ) and grade, which together define low-, intermediate-and high-risk stratification categories, and an approach common to all major international guidelines [3] [4] [5] .
Transurethral resection of bladder tumour (TURBT) to remove these superficial tumours is the standard clinical procedure performed by urologists for the treatment of NMIBC [6] [7] [8] . To reduce the risk of cancer recurrence after TURBT, adjuvant intravesical chemotherapy (delivery into the bladder via a catheter) is generally recommended. For lowand intermediate-risk NMIBC tumours, a single instillation of mitomycin C (MMC) is the standard of care (doxorubicin and epirubicin are also recommended in various clinical guidelines) [3, 5] . Postoperative intravesical therapy can eliminate residual tumour cells released into the bladder during surgery that could re-seed new tumours, and kill cancer cells in tumour margins that remain after surgery or in tumours not resected during surgery [5] . Intermediate-risk tumours may also be treated with a multiple-dose induction course of chemotherapy or immunotherapy, with BCG vaccine, in order to prevent progression of the disease. In addition to recommended agents, other drugs are emerging in clinical studies for intravesical chemotherapy, including, thiotepa, gemcitabine [9] [10] [11] , and taxanes (paclitaxel [PTX] and docetaxel [DTX] ).
Notwithstanding established best practices, low adherence to guidelines in NMIBC therapy is well-known [12] , due to limitations in efficacy and tolerability risks of the standard of care agent. Indeed, efficacy of postoperative MMC is limited to only a 10-15% overall reduction in 1-and 2-year posttreatment recurrence rate [4] . The high rate of tumour recurrence mandates lifetime surveillance of the patient, leading to high healthcare costs [13] .
The limited therapeutic benefit from current intravesical chemotherapy protocols is thought to arise from either a lack of sensitivity of bladder cancer cells to the drugs or from poor exposure of drug to the cancer cells [14, 15] . Therefore, much research has focused on improving drug delivery with new formulations or potentially synergistic combined drug treatments. In one recently published multi-institutional study, the sequential instillation of two drugs into patient bladders was described; gemcitabine (1 000 mg) for 90 min, removal followed by 90 min incubation with 40 mg MMC. After 2 years, 14 of a total of 47 patients remained recurrence free, whereas 10 patients required cystectomy [16, 17] . Other studies evaluated the combination effect of gemcitabine with platinum compounds and taxanes (gemcitabine + DTX) [18] [19] [20] [21] [22] . Delivery strategies such as encapsulating MMC in chitosan nanoparticles, electromotive drug administration or hyperthermia associated delivery of MMC are also under investigation to improve existing treatment approaches [23] [24] [25] [26] [27] [28] [29] . Improved delivery strategies have been applied to single dose, multi-dose induction, and even experimental presurgical intravesical chemotherapy protocols.
Recently, we have investigated the use of a cationic nanoparticulate (CNP) drug-delivery system for the anticancer drug DTX, based on the use of amine functionalised polyglycerols (CNP-DTX) as mucoadhesive drug carriers. This formulation allowed for increased DTX uptake into bladder tissue as compared to the use of Taxotere (the commercial formulation of DTX). Treatment of bladder tissue with CNPs resulted in the disruption of the surface morphology of the lumen surface, so that the barrier properties were transiently reduced, allowing drug to diffuse into the tissue. The degree of exfoliation of umbrella cells was shown to be proportional to the CNP concentration and the amine density on the CNP. On the other hand, the Tweenbased formulation of DTX (Taxotere) has no exfoliating effect on the bladder and was associated with low drug tissue levels and limited efficacy [30, 31] . This strategy of using CNPs to both solubilise the DTX and to exfoliate and permeabilise the bladder tissue has proven successful in treating orthotopic bladder tumour xenografts in mice [30] [31] [32] [33] .
The amine-containing, water soluble anticancer drugs doxorubicin, MMC and gemcitabine are all used for the intravesical treatment of bladder cancer but their effect on the integrity of the bladder urothelium is not completely understood. There have been some reports of inconsistent levels of exfoliation seen in human bladders treated with doxorubicin and MMC clinically [34, 35] . We hypothesise that amine-containing chemotherapy drugs will interact with the surface of the bladder resulting in exfoliation, allowing greater penetration into the bladder tissue of a second agent (a taxane). The objective of the present study was to investigate the effects of doxorubicin, MMC and gemcitabine on intact pig bladder urothelium and to compare the uptake of these drugs, and taxanes, into the bladder tissue with or without prior treatment with urothelium-exfoliating CNPs.
Materials and Methods

Materials
The amine conjugated cationic polyglycerol (CNP-580) was synthesised and characterised by our group as previously described [30, 36] . The degree of amine group substitution is represented by the number of micromoles (x) of amine per gramme of hyperbranched polyglycerol and is denoted by CNP-(x), where x is 580 lmol of amine per gramme of CNP [30] . All solvents were HPLC grade and were purchased from Fisher Scientific (Ottawa, ON, Canada 
Porcine Bladder Tissue
Pig bladders (from 6 to 10-month-old male pigs weighing 90-113 kg) were purchased from Britco Inc. (Langley, BC, Canada) and were used within 5 h of harvesting.
Preparation of Drug Solutions for Drug-Uptake Studies
Mitomycin C, gemcitabine and doxorubicin solutions were prepared by dissolution in Tyrode's buffer (pH 6.4) at 1 mg/ mL. MMC and gemcitabine solutions were doped with 20 lCi of 3 H-labelled mitomycin or gemcitabine, respectively, prior to incubation with bladder tissue. The doxorubicin solution was doped with 14 C-doxorubicin (50 lCi). The CNP-580 (10% w/v) solution used for pretreatment studies was prepared by dissolving the CNP in Tyrode's buffer (pH 6.4).
Preparation of Taxane and Chemotherapeutic Drug Solutions for Drug Uptake
Taxol or taxotere were mixed with Tyrode's buffer (pH 6.4) to a drug concentration of 0.5 mg/mL. MMC, doxorubicin or gemcitabine dry drug was co-dissolved in taxane solutions at 1 mg/mL concentration. Taxotere solutions were doped with a small amount of radiolabelled drug (~20 lCi).
Tissue Sample Preparation
Unwanted adipose tissue was removed from porcine bladders, which were opened into left and right lateral sides and cut into pieces of~2 9 2 cm in a shallow bath of 37°C Tyrode's buffer. Bladder studies were performed within 5 h of harvesting. Bladder pieces were placed onto the base plate of a Franz diffusion cell apparatus without stretching, such that the luminal side of the bladder wall was exposed to the drug solution.
Ex vivo Exfoliation Studies
Scanning electron microscopy was used to observe and characterise urothelial morphology. Freshly excised porcine bladders tissues were mounted onto a Franz diffusion cell apparatus [30, 31] . Receptor chambers were filled with Tyrode's buffer (pH 7.4) to ensure the non-urothelial side was moist. The donor chambers (urothelial side) were filled with 0.5 mL of either Tyrode's buffer (pH 6.4 for a control), otherwise CNP-580 (10% w/v), MMC (1 mg/mL), doxorubicin (1 mg/mL) or gemcitabine solutions (1 mg/mL) were placed in the donor cell and incubated at 37°C for 2 h. After incubation and tissue washing in Tyrode's (pH 7.4), the bladder tissues were fixed with a solution of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) and kept at 4°C for 3 h. The buffer was then changed to 0.1 M sodium cacodylate buffer (pH 7.4) for 18 h at 4°C and later fixed with in osmium tetroxide for 1 h at room temperature. The samples were dehydrated in acetone (increasing from 30% to 100%), critical point dried, and coated with gold-platinum. Scanning electron microscopy was performed using a Hitachi S4700 scanning electron microscope.
Drug-Uptake Studies
In some studies the bladder sections were pretreated with CNP-580 and Tyrode's buffer (37°C, pH 7.4) was placed in receptor chambers and the donor chambers were filled with 0.5 mL of CNP-580 (10% w/v in Tyrode's pH 6.4) solution or 0.5 mL of Tyrode's pH 6.4 alone. After incubation for 1 h at 37°C the tissues were washed three times with Tyrode's buffer pH 7.4. For drug-tissue incubations, 0.5 mL of either 1 mg/mL MMC, doxorubicin or gemcitabine, or mixtures of these with 0.5 mg/mL of taxane (DTX or PTX) was placed in the donor chamber and the tissues were incubated at 37°C for 2 h. All tissue samples were then removed, trimmed and rapidly frozen with liquid nitrogen onto metal plates (the urothelial side downwards to ensure a flat surface).
Cryotome Sectioning of Tissue
Frozen bladder tissue was mounted and sectioned (60 lm) at À20°C on a Shandon Cryotome Electronic (Thermo Electron Corporation, Cheshire, UK) with a R404A refrigeration system. Urothelium tissue sections between 60 and 240 lm were collected individually for analysis. For the lamina propria, two tissue sections (both 60 lm) were collected between depths of 240 and 1260 lm and pooled for analysis. Three tissue sections between 1260 and 2160 or 3060 lm (muscle layer) were pooled for analysis. Tissue sections were weighed and frozen at À20°C.
Quantification of Drug in Tissue
Acetonitrile (200 lL) was added to the weighed tissue slices for drug extraction in 1.5-mL microcentrifuge tubes followed 900 © 2018 The Authors BJU International © 2018 BJU International by vortexing until all tissue slices were completely submerged in acetonitrile and left at room temperature for 24 h to ensure full extraction of drug. The extracted samples, including all tissue slices, were placed in scintillation vials for drug analysis by liquid scintillation counting and quantified using calibration graphs from the original stock solutions. Statistical analysis of drug penetration results for MMC, doxorubicin and gemcitabine at each tissue depth with or without pretreatment with CNP-580 (10%w/v) was performed using the unpaired t-test.
Haematoxylin and Eosin Staining
In some studies, paraffin-embedded bladder sections were cut individually, stained and imaged by light microscopy. Briefly, slides were warmed to 60°C and then deparaffinised and rehydrated through xylene, 100% alcohol, 95% alcohol, and water. Tissue sections were then stained with Gill's haematoxylin, 1% acidic alcohol, lithium carbonate and eosin solution with a water wash in between each stain. Sections were then dehydrated and cleared using 95% alcohol, 1% alcohol, and xylene. Sections were then encased in Permount mounting medium, cover slipped, and imaging was done using light microscopy.
Results
Tissue Depth Penetration Profiles of MMC, Doxorubicin or Gemcitabine and the Effect of Pretreatment of Bladder Tissue with CNPs
In studies where tissues were pretreated with either buffer (Tyrode's pH 6.4) or CNP-580 (10% w/v) followed by incubation with MMC, doxorubicin or gemcitabine drug solutions, all drugs penetrated the bladder wall to some degree. MMC penetration levels reached 100 lg/g up to a tissue depth of 750 lm with a gradual decrease in drug concentration after that (Fig. 1) . Pre-incubation of tissues with CNP-580 (10% w/v) had little effect on tissue concentrations of MMC, with no difference either in the total amount of drug that had penetrated the tissues or the amount of drug at any specific depth. Qualitatively, doxorubicin penetrated tissues less than MMC. The drug concentration at a tissue depth of 350 lm was~75 lg/g followed by a rapid decline in concentration at deeper levels (Fig. 2) . Pretreatment with CNP-580 (10% w/v) had no effect on tissue concentrations of drug.
Gemcitabine penetrated bladder tissue and maintained drug concentrations in the 75-100 lg/g of tissue range at depths of 1000 lm. At deeper levels, drug concentrations fell off slowly but the drug was still detected at 25 lg/g levels at a depth of 2250 lm (Fig. 3) . Pre-incubation of tissue with CNP-580 (10% w/v) had no effect on drug uptake. These experiments were performed in sets of three using different bladder samples at different times. After each experiment, there was no clear trend showing any difference in drug uptake values between CPG-pretreated tissues and drug-alone tissues, and these findings were supported by t-test analysis of data at various depth points. Further experiments were carried out to increase the numbers (to a final of n = 15 samples) and still no evidence of any difference was seen. At this point an investigation into the effects of drug alone on possible tissue exfoliation commenced and no further experiments were performed looking at CPG pretreatment effects. (Fig. 4) . Drug concentrations then gradually dropped to ≤20 lg/g of tissue at a depth of 1250 lm. For DTX, the penetration of the drug was enhanced after pretreatment of the bladder with CNP-580 (10% w/v) (Fig. 4) . The simultaneous treatment of tissue with DTX and MMC gave the highest DTX concentrations in tissue, >100 lg/g dropping to~60 lg/g of tissue at a depth of 700 lm. Similarly, the treatment of tissue with DTX combined with either doxorubicin or gemcitabine also gave enhanced levels of DTX uptake across the lamina propria layer (to depths of~1250 lm; Fig. 4 ).
Paclitaxel penetrated bladder tissues at lower levels than those observed for DTX, so that when presented as Taxol alone, tissue levels remained low (<10 lg/g of tissue) throughout all layers of the tissue (Fig. 5) . The pretreatment of tissues with CNP-580 (10% w/v) enhanced the uptake of PTX throughout the bladder tissue, reaching levels of~20 lg/g in the urothelium and between 20 and 10 lg/g of tissue though most of the lamina propria. The treatment of bladder tissue with Taxol combined with MMC, doxorubicin or gemcitabine also resulted in enhanced PTX uptake throughout the whole depth profile of the tissue, with 150% (with doxorubicin) and 200% (with MMC or gemcitabine) higher PTX concentrations in the lamina propria (Fig. 5) . Doxorubicin had an enhancing effect allowing for increased drug levels similar to those seen after pretreatment with CNP-580 (Fig. 5) . The coadministration of PTX with either MMC or gemcitabine resulted in similar levels of enhanced PTX uptake as seen with doxorubicin with concentrations of PTX in the lamina propria approximately double those found with Taxol alone treatment.
The total exposure of taxanes in the bladder (Fig. 6A,B) was calculated as the concentration area under the curve (AUC) from the tissue depth profiles in Figs 4 and 5. For both drugs the combined treatment of bladder tissue with taxane along with either gemcitabine or MMC approximately doubled the AUC value. On the other hand, doxorubicin increased overall DTX uptake by~50% and PTX by~150%. CNP-580 (10% w/ v) pretreatment of bladder tissue resulted in similar AUC increases for DTX and PTX, at 80% and 150%, respectively.
Bladder Exfoliation Studies by Scanning Electron Microscopy
Treatment of bladder tissue with Tyrode's buffer alone had no effect on tissue morphology as seen by an intact, tightly packed umbrella cell urothelial layer shown in Fig. 7A . However, the incubation of tissue with CNP-580 (10% w/v) resulted in the majority of umbrella cells being exfoliated from the surface with just a few loosely attached cells remaining (Fig. 7B) . Similarly, both MMC and doxorubicin caused extensive exfoliation of the urothelial surface, characterised by complete removal of cells from some areas or loosely attached cells only in other areas (Figs 8,9 ). Gemcitabine induced milder exfoliation with areas of missing Tissue was exposed to 1 mg/mL GEM for 2 h or pretreated with CNP-580 (10% w/v) for 1 h, followed by a 2-h treatment with GEM (1 mg/mL).
Values are means AE SEM (n = 15). (Fig. 10) .
MMC-DTX/
Exfoliation Studies Using Histopathological H&E Staining
Histopathological haem and eosin (H and E) staining of bladder tissues exposed to drugs or CNP-580 (10% w/v) showed similar patterns of exfoliation as seen with scanning electron microscopy ( Fig. 11) . Bladder tissue was unaffected by treatment with Tyrode's buffer (pH 6.4) as seen by an intact urothelium on the bladder surface (Fig. 11A) . On the other hand, MMC caused a stripping of urothelium from the underlying tissues (Fig. 11B) , with similar results seen (missing urothelium on bladder tissue) when tissue was exposed to doxorubicin (Fig. 11C) . Gemcitabine treatment of bladder tissue resulted in only minor levels of exfoliation, as seen by some missing umbrella cells but little evidence of missing sections of umbrella cells (Fig. 11D) , as previously observed for the other drugs and CNP-580 (10% w/v).
Discussion
Transurethral resection of bladder tumour is an effective method to eliminate bladder cancer in~55% of patients with NMIBC. The remaining 45% will experience recurrence or GEM (1 mg/mL). Some tissues were pretreated with CNP-580 (10% w/v) for 1 h followed by PTX (0.5 mg/mL). The data were compared between control and treatments by one-way ANOVA and significance is shown with P values (*P < 0.05 and **P < 0.001).
© 2018 The Authors BJU International © 2018 BJU International 903 within 1 year [37] , at a frequency related to the patient's risk stratification [38] . Whilst current chemotherapeutic modalities (single instillation of drugs, such as MMC) have a modest impact (10-15%) on short-term recurrence, long-term effects are not established. While single dose MMC can prevent recurrence; induction and maintenance therapy, with multiple doses of BCG (with or without chemotherapy), is required to prevent progression [4, 5] , but also with limited effectiveness.
There is an obvious need for improved adjuvant intravesical chemotherapy after TURBT and recent research has focused on the use of agents such as gemcitabine, and taxanes including PTX and DTX, including combinations of taxanes with gemcitabine. Both gemcitabine and taxanes are potent inhibitors of bladder cancer cell growth and are used systemically for the treatment of advanced bladder cancer (including in combination). Also, numerous clinical studies have evaluated their use as intravesical therapy ( [39, 40] for DTX; [41] for GEM).
Because taxanes have low water solubility, they are formulated in micelles using Cremophor (PTX) or Tween 80 (DTX), which may limit their delivery to bladder tissue due Fig. 9 Scanning electron micrograph of porcine bladder urothelium after exposure to doxorubicin (1 mg/mL) for 2 h, shows region of exfoliation of urothelium (red arrow).
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© 2018 The Authors BJU International © 2018 BJU International to effects of formulation excipients [42] . We, using CNPs, and others, using chitosan, have shown that delivery of these hydrophobic agents using delivery systems containing amine functionality can improve uptake of taxanes into bladder tissue [24, 31] . These CNPs (particularly CNP-580) successfully caused exfoliation of the urothelial tissue, allowing for enhanced DTX uptake to effectively inhibit human orthotopic bladder tumour growth in mice [30, 31, 33] .
As we have shown that CNP-580 causes exfoliation in the ex vivo pig bladder tissue model, it was possible that the pretreatment of bladder tissue with these CNPs alone might allow for the subsequent enhanced uptake of water soluble drugs like MMC (the first-line adjuvant therapy for patients with low-grade NMIBC), doxorubicin, and gemcitabine. However, in the present study, there was no measurable enhancing effect of CNP-580 pretreatment of tissues on the uptake of these drugs (Figs 1-3 ). All three drugs penetrated the important lamina propria layer to a similar extent with or without pretreatment. Our present results are also similar to other published data. Wientjes et al. [43] also determined that MMC penetrated bladder tissue (dog) well, but tissue levels were highly variable with an average value of 24 lg/g using a drug dose of 0.5 mg/mL, as compared to our present findings of levels as high as 100 lg/g using a dose of 1 mg/L in porcine bladder. Changes to tissue morphology were consistent with drug concentration data. Scanning electron microscopy observations showed that all three drugs elicited an exfoliation effect in the bladder tissue (Figs 7-10) individually, in support of the hypothesis of the present study. Accordingly, any pretreatment of the bladder with CNP-580 would have little additional effect on the permeability status of the urothelium, which might be similarly exfoliated by each of the three drugs. These data showed that MMC caused extensive exfoliation, doxorubicin caused moderate exfoliation, and gemcitabine caused urothelial cell weakening and partial exfoliation. As all three drugs contain positively charged amine groups, it is likely that these moieties bind to the negatively charged bladder tissues, disrupting urothelial cell homeostasis, similar to the mechanism of exfoliation induced by CNP-580. In a detailed characterisation of the effect of CNP-580 on bladder tissues, we have recently reported that the degree of exfoliation caused by aminated CNPs is proportional to the polymer concentration and the density of amine groups on the macromolecule [44] . In that study, we also observed that DTX alone had no exfoliating effect. As MMC contains two amine groups per molecule, it is likely that the extensive exfoliation seen with this drug may arise from the higher amine concentration as compared to the single amines on doxorubicin and gemcitabine. The exfoliating effects of other amine-containing compounds such as chitosan [45] , protamine [46] , and cationic peptides, have been reported. However, this is the first comprehensive report and characterisation, to our knowledge, of the effect of these three drugs (MMC, doxorubicin and gemcitabine) on the bladder wall.
The scanning electron microscopy observations of the different levels of exfoliation caused by these drugs were supported by histopathological studies showing urothelial layers stripped off to various degrees from the underlying tissue after exposure to either MMC or doxorubicin, whereas gemcitabine caused much less disruption (Fig. 11) . Having established that MMC, doxorubicin and gemcitabine all cause exfoliation of bladder tissue, as did the CMP-580 polymer in this model, we investigated whether simultaneous administration of these drugs with commercial formulations of taxanes might also increase taxane uptake. Indeed, all three drugs allowed for significant increases in both PTX and DTX uptake through the tissue (Figs 4-6 ). These effects are clearly seen in the tissue-depth profiles. These increases may be expressed in terms of total drug exposure when the areas under the concentration-tissue depth curve (AUCs) are compared in the appropriate layers and these were in the range of 50-150%. These increases were significant for all drug treatments, as compared to drug levels achieved with the commercial formulations of the taxanes alone.
The effects of each of MMC, doxorubicin and gemcitabine on taxane uptake were assessed at a fixed concentration of 1 mg/ mL, for consistent comparison between groups with respect to the effect of amine concentration. However, this method has limitations. First, MMC has two amine groups while the other two agents have one, so it may be argued that a higher effective amine exposure is achieved with this compound. Similarly, pKa values of the ionisable amine groups and the molecular weight of the compound are not factored in, thus the 1 mg/mL drug concentration provides comparable levels, but not a quantitative comparison of amine exposure. Finally, it ignores differences in the typical therapeutic dosing range for these intravesical agents which is~1 mg/mL for both MMC [47] and doxorubicin [48] , and 20-40 mg/mL for gemcitabine [41] . Based on this, one may expect that gemcitabine could elicit an even greater effect on taxane uptake into tissues at its 20-times higher therapeutic dose. Based on our positive results reported here with respect to the effect of amine, evaluating different agents at a single dosage, further characterisation of dose response is warranted. For this future experiment, a single agent can be compared at different concentrations. Gemcitabine represents the best candidate for continued study, as a 20-40 times increase in drug concentration may be safely administered, in contrast to MMC and doxorubicin which cannot be administered at a concentration substantially higher than the 1 mg/mL dose level already evaluated.
The findings of the present study are important, as they help to predict the behaviour of clinical standard-of-care agents, and to better understand new candidates for intravesical therapy (gemcitabine and taxanes). The results explain potential benefits, or highlight the potential for protocol optimisation with respect to parameters such as drug concentration and pH of the instillation solution. In the case of combined therapy protocols, the impact of compound chemistry can be considered in terms of drug-drug 906 © 2018 The Authors BJU International © 2018 BJU International interaction potential, and the impact of sequencing drug administration. For example, these data predict that administration of gemcitabine followed by DTX could result in different DTX exposure to the patient then treatment with DTX followed by gemcitabine. Alternately, the kinetics of the effect described by these data could be determined (e.g. what is the duration of the transient effect on tissue penetration of amine exposure) in order to optimise the period of time to wait between dosing in combined therapy, depending on the desired outcome.
It is important to realise that the ex vivo pig bladder model has limitations, in that although the tissue is fresh and metabolically active, there is a lack of an active blood supply to the tissue. Therefore, there is no drug clearance from the area, which might impact findings.
Interestingly, when considering the structures of other major anticancer drugs, it is of note that most do not contain amines in their structure (e.g. vinca alkaloids, etoposide, mitoxantrone, camptothecin topotecan and ironotecan, cyclophosphamide, 5-fluorouracil). However, some other anticancer drugs are aminated and include methotrexate (two amines), the camptothecin analogue exatecan, and the platinum drugs cisplatin and carboplatin. In a previous studies that did not investigate exfoliation events, we found that the co-administration of cisplatin and PTX allowed for good drug uptake of both agents in mice with some leakage into the systemic circulation [49] , which in retrospect may have arisen from a cisplatin-induced exfoliation effect. Further studies in this laboratory will examine taxane uptake and exfoliation effects in the bladder using co-administration methods with these other drugs (namely cisplatin, carboplatin, methotrexate or exatecan). These new studies may further elucidate preferred dual drug combinations for intravesical chemotherapy that may permit for the optimal penetration of the drugs without the risk of unwanted systemic uptake.
